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Abstract
Previously we have shown cationic lipid (R)-DOTAP as the immunologically active enantiomer of
the DOTAP racemic mixture, initiating complete tumor regression in an exogenous antigen model
(murine cervical cancer model). Here, we investigate the use of (R)-DOTAP as an efficacious
adjuvant delivering an endogenous antigen in an aggressive murine solid tumor melanoma model.
(R)-DOTAP/Trp2 peptide complexes showed decreasing size and charge with increasing peptide
concentration, taking a rod-shape at highest concentrations. The particles were stable for at 2
weeks at 4°C. A dose of 75nmol Trp2 (formulated in (R)-DOTAP) was able to show statistically
significant tumor growth delay compared to lower doses of 5 and 25nmol which were no different
than untreated tumors. (R)-DOTAP/Trp2 (75nmol) treated mice also showed increased T cell IFN-
γ secretion after restimulation with Trp2, as well as CTL activity in vivo. This vaccination group
also showed the highest population of functionally active tumor-infiltrating lymphocytes,
indicated by IFN-γ secretion after restimulation with Trp2. Thus, (R)-DOTAP has shown the
ability to break tolerance as an adjuvant. Its activity to enhance immunogenicity of other tumor
associated antigens should be studied further.
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Introduction
Recent clinical advances for the treatment of melanoma have great potential to
revolutionalize the field, however not without associated toxicity. The recent FDA approval
of the anti-CTLA4 antibody ipilimumab for unresectable and metastatic melanoma shows a
step forward for biological drugs and immunotherapy for melanoma However, the approval
also came with a boxed warning for immue-related adverse events (irAE) which can range
from mild to severe.1 Interestingly, the severity of irAE seemed to correlate with a positive
response to therapy.2
Intensive research on the genetics of melanoma have led to advances in small molecule
inhibitors as well.3 Several companies are investigating drugs for melanomas with oncogene
mutations, most notably, BRAF V600E which occurs in almost 50% of melanoma cases.4
The recent approval of vemurafenib showed up to an 81% response rates in trials.5 Other
small molecule BRAF inhibitors are still in the clinical trials and include RAF-265, XL281,
and GSK2118436. However, even with promising BRAF inhibitors selective for patients
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with the V600E mutation, side effects are seen, such as resectable cutaenous carcinoma, and
more importantly, induction of resistance.1, 5, 6 With side effects produced by the new
frontier of both biological and small molecule drugs for melanoma, there is still space to
innovate a treatment that is able to treat aggressive tumors with fewer off-target effects.
As a treatment option, peptide vaccines offer the safety and specificity of a restricted
epitope. Specific antigen in the form of peptide sequences (8–10 amino acids long) can be
delivered to antigen presenting cells (APCs). Restricting the sequence choice to bind to
major histocompatibility complex (MHC) class I ensures CD8+ T cell engagement.
Activation of APCs and presentation of the peptide can stimulate a corresponding cytotoxic
T lymphocyte (CTL) response against the epitope. As an antigen, peptides are easy to
manufacture and specific, however, they are rarely immunostimulatory alone. Dendritic cells
pulsed with melanoma tumor-specific peptide were unable to stimulate a therapeutic
response when injected on the same day as the tumor.7 Delivery of a peptide antigen with an
adjuvant is required for potent activation of APCs, and associated CTL activity.
In the case of melanoma, sensitizing CTLs against the corresponding endogenous, or self-
antigen poses yet another challenge. As T cells develop in the thymus, self-reactive T cells
are deleted, and regulatory T cells develop in circulation and particularly in the presence of
tumors. Some have taken the approach to genetically modify T cell receptors to be specific
for tumors, instead of efforts to vaccinate and allow a response to develop in an aided
fashion.8 A strong adjuvant would be required to break through this tolerance and stimulate
a powerful anti-tumor response.
While many melanoma peptide antigens are well characterized, tyrosinase-related protein 2
(Trp2) is particularly attractive as an antigen. Trp2 peptide (amino acids 180–188 of the
Trp2 protein, sequence: SVYDFFVWL) is MHC class I H-2Kb restricted in mouse, allowing
for examination of a CD8+ CTL response. The sequence is also HLA-A2 restricted, thus the
potential exists for the same formulation to be tested both in mouse and in humans.
Additionally, since melanoma and glioma cells are both neuroectodermal in origin, Trp2 is
also expressed in this additional cancer line, allowing for a natural secondary application of
any developed formulation 7, 9. However, as delivery cargo, Trp2 peptide is hydrophobic
and difficult to formulate in an aqueous solution or delivery vehicle. The most successful
work with Trp2 peptide as an antigen has been with preventative models.10–13 Few studies
examine the treatment of established tumors, and none to date have shown any effect in
aggressive solid tumor models.14–16
Previously, our group has studied DOTAP lipid as an adjuvant in peptide and protein
vaccine formulations. A DOTAP/peptide vaccine has shown complete tumor regression in
an exogenous antigen model.17, 18 Further investigation of the DOTAP lipid, showed chiral
specificity of the adjuvant activity.18 These studies led us to discover (R)-DOTAP as the
active immune-stimulating enantiomer. (R)-DOTAP (or even the DOTAP racemic mixture)
has never been tested as an adjuvant in an endogenous tumor model, and indeed the
challenges of breaking tolerance are not slight. Particularly, treating an established tumor
model in melanoma is rarely tested due to the difficulty of generating an adequate immune
response to cause tumor growth delay due to the suppressive effects of an established tumor.
In work presented here, we address the formulation challenges of delivering an adequate
dose of the innately hydrophobic Trp2 peptide and utilize (R)-DOTAP/Trp2 complexes in
an advanced melanoma model to break tolerance and show statistically significant tumor
growth delay.
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(R)-DOTAP [(R)-1,2-dioleoyl-3-trimethylammonium-propane] was obtained from Merck
KGaA (Darmstadt, Germany). H-2Kb restricted peptides Trp2 (H-SVYDFFVWL-OH,
amino acids 180–188 from the tyrosinase-related protein 2 over-expressed in human and
murine melanoma, MW 1175) and Ova (H-SIINFEKL-OH, amino acids 257–264 from the
ovalbumin, MW 1773) were obtained from Peptide 2.0 (Chantilly, VA), supplied as
trifluoracetate salts. Molecular biology grade water was obtained from Cellgro (Manassas,
VA). Sodium methoxide, pure titrant (0.5M in methanol) and HPLC grade methanol were
obtained from Fisher Scientific (Pittsburgh, PA). Absolute ethanol was obtained from Decon
Labs, Inc. (King of Prussia, PA).
Trp2 peptide preparation
Specific weights of Trp2 peptide were dissolved in a 1:1 solution of methanol:ethanol. Serial
dilution of Trp2 peptide was measured on a Shimadzu UV-Vis spectrophotometer (model
UV-2501 PC, Columbia, MD), and absorbance recorded. The measurements were made in
triplicate, and standard curve created utilizing the Beer-Lambert law. The extinction
coefficient, ε = 5,367.7 (M−1cm−1), was found with the measured absorbance at 280nm
wavelength to estimate Trp2 peptide concentration and encapsulation.
Trp2 peptide was formulated as a disodium salt for delivery. Peptide arrived as a
trifluoroacetate salt and was dissolved in HPLC grade methanol in a glass vial and a
magnetic stir bar added. The peptide was stirred in an ice bath, as two equivalents of sodium
methoxide were added drop wise. Titrated peptide was allowed to stir for 10min as the
solution became clear. Aliquots of the peptide solution were added to water and pH
measured (pH 9). Methanol was dried off using a rotoevaporator, and peptide was
resuspended as a 1.5mM working concentration in molecular biology grade water.
Preparation and Evaluation of Vaccine Formulations
Briefly, 6,000nmol of (R)-DOTAP dissolved in chloroform was dried in a glass vial under a
stream of nitrogen and stored under vacuum in a desiccator overnight to ensure removal of
any remaining chloroform. Lipid/peptide complexes were formed by thin film hydration,
using a 1mL solution of Trp2 peptide at different concentrations in molecular grade water
(Cellgro, Manassas, VA) and subsequent vortexing. After 1h at room temperature, the
suspensions were extruded ten times through two 100nm polycarbonate membranes (Fisher
Healthcare, Houston, TX).
Particle size and zeta potential were measured with a Malvern Zetasizer Nano ZS
(Worcestershire, United Kingdom). Samples were prepared for size and charge
characterization by adding 10µL 6mM (R)-DOTAP/(1.5 to 0mM) Trp2 complexes to 990µL
of molecular biology grade water. Trp2 peptide encapsulation efficiency was measured by
adding 50µL of extruded lipid/peptide complexes to a Microcon 100kDa molecular weight
cut off centrifugal filtrate device (Millipore, Bedford, MA). The column was centrifuged at
10,000g for 10min at 25°C. Flow-through was analyzed using 2µL of sample on a Nanodrop
Spectrophotometer, ND-1000 (Thermo Scientific, Wilmington, DE), measuring the
absorbance at 280nm wavelength. Concentration of peptide in flow-through
(unencapsulated) was calculated using Beer-Lambert law (A280 = ε*b*c), with ε = 5,367.7
(M−1cm−1), calculated from a standard curve of Trp2 peptide. Final encapsulated
concentration was calculated by subtracting the concentration in flow-through from the
known concentration used for hydration. Trp2 peptide loss in the column was < 5%.
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Transmission electron microscope (TEM) images of the (R)-DOTAP/Trp2 complexes were
acquired by the use of a JEOL 100CX II TEM (Tokyo, Japan). Briefly, 4µl of nanoparticle
solution was dropped on to a 300 mesh carbon coated copper grid (Ted Pella, Inc., Redding,
CA) for 2min. Excess fluid was removed with filter paper, and copper grid was dried before
the observation with TEM. A total of 210 particles from 3 different fields were measured.
Particle dimensions were calculated by measuring the longest dimension and the
perpendicular diameter.
Tumor cell culture
B16F10 cells, a murine melanoma model (syngeneic with C57BL/6) were originally
obtained from American Type Culture Collection (ATCC) (Manassas, VA). Previously, in
collaboration with Dr. Pilar Blancafort at the University of North Carolina at Chapel Hill
(UNC), B16F10 was stably transfected with GL3 firefly luciferase gene using a retroviral
vector to create B16F10-luc.19, 20 B16F10-luc cells were used in all studies presented here
and maintained in Dulbecco’s Modified Eagle Medium (Gibco (Invitrogen), Carlsbad, CA)
supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA), 100U/mL
penicillin (Invitrogen) and 100µg/mL streptomycin (Invitrogen).
Mice and Immunizations
Six week old female C57BL/6 mice obtained from the National Cancer Institute, were used
in all studies. On day 0, 3x105 B16F10-luc cells in 50µL of PBS were injected
subcutaneously into the hair-trimmed abdomen. On day 6, formulations were
subcutaneously injected into the contralateral side of the abdomen in 100µL of 5% dextrose
solution. In all experiments, 300nmol (R)-DOTAP per mouse was the therapeutic dose of
adjuvant used, as shown by our lab previously.18 Tumors were measured every 2–3 days
with calipers, recording the longest diameter as length and the perpendicular dimension as
width. Area was calculated as (length)×(width). Humane sacrifice of mice was performed
after tumors reached 20mm in one dimension. All animal protocols were approved by the
University of North Carolina at Chapel Hill’s Institutional Animal Care and Use Committee.
Multi-organ interferon gamma (IFN-γ) production by CD8+ T cells
Mice were inoculated with 3x105 B16F10-luc cells on day 0. On day 6, mice were
vaccinated with varying doses of (R)-DOTAP/Trp2 (with R-DOTAP at a constant dose of
300nmol/mouse). On day 13, mice were sacrificed and spleen, vaccine draining lymph node
(right inguinal) and tumor draining lymph node (left inguinal) were removed from each
mouse in a sterile hood. Organs were processed into a single cell suspension by crushing
through a 70µm filter (BD Biosciences, San Jose, CA). After removal, cells were incubated
in Roswell Park Memorial Institute (RPMI) 1640 media supplemented with FBS, non-
essential amino acids (NEAA) (Cellgro), antibiotic/antimycotic (Cellgro), 1µL/mL
GolgiStop™ (BD Biosciences) and 5µM Trp2 or Ova peptide for 6h at 37°C. Cells were
removed, washed with staining buffer (BD Pharmingen, San Diego, CA) and stained with
anti-CD8 (clone 53-6.7). Cells were then treated with Cytofix/Cytoperm™ according to kit
instructions (BD Pharmingen) and stained intracellularly with anti-IFN-γ (clone XMG1.2),
washed and analyzed with a FACS Canto flow cytometer (BD Biosciences) and analyzed
with FACS Diva software (BD Biosciences).
In vivo Cytotoxic T Lymphocyte (CTL) Assay
The in vivo CTL assay has been described previously and was performed here with slight
modifications.18, 21 Briefly, mice were inoculated with 3x105 B16F10-luc cells on day 0 and
vaccinated with (R)-DOTAP/Trp2 formulations on day 6. Seven days later, naïve mice were
sacrificed and splenocytes removed. Splenocytes were pulsed with either 10µM Trp2 or Ova
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peptide for 1–2h in complete media at 37°C. Cells were stained with carboxyfluorescein
succinimidyl ester (CFSE) (Sigma-Aldrich, St. Louis, MO), with Ova peptide-pulsed and
Trp2 peptide-pulsed cells stained with 0.4 and 4µM, respectively in serum free RMPI 1640
media for 15min. Cells were then washed with complete media (RMPI 1640 with FBS,
NEAA and antibiotic/antimycotic) and counted. Equal numbers of CFSEhigh (Trp2-pulsed
cells) and CFSElow (Ova-pulsed cells) were mixed together and stained with 8µM PKH-26
(Sigma-Aldrich) according to manufacturer’s instructions. Vaccinated mice were injected
with 107 labeled cells and in vivo killing of the targets was allowed to take place for 22h.
After that time, spleens from treated mice were removed and processed into a single cell
suspension and red blood cells lysed with ACK lysing buffer (Invitrogen). Cells were
washed in complete media and resuspended in phosphate buffered saline (Sigma-Aldrich).
The cells were analyzed with a FACS Canto flow cytometer (BD Biosciences) and FACS
Diva software (BD Biosciences), first gating for the lymphocyte population, then for the
PKH-26 positive cells, to determine the amount of specific lysis of the CFSEhigh Trp2-
pulsed cells. The following equation from 21, describes Ova and Trp2 representing the
number of peptide-pulsed cells present after the in vivo killing time allotment.
Tumor Infiltrating Lymphocyte Analysis
B16F10-luc tumors from mice vaccinated on day 6 were removed on day 13 in a sterile
environment. Tumors were minced and processed through a 70µm strainer to form a single
cell suspension. Cells were blocked with Fc block (anti CD16/CD32 (clone 2.4G2)) for 15
min, then stained with anti-CD3 (clone 145-2C11), anti-CD8 (clone 53-6.7) and anti-CD4
(clone RM4-5) and analyzed by flow cytometry.
Functionality of Tumor Infiltrating Lymphocytes
Alternately, lymphocytes were isolated from the tumors. Tumors were prepared as a single
cell suspension (described above). The cells were washed and resuspended in complete
media. Tumor infiltrating lymphocytes (TIL) were separated from the tumor using Ficoll-
Paque™ PLUS (GE Healthcare, Uppsala, Sweden), a density gradient method. Briefly, the
single cell suspension of tumor cells were resuspended in 8mL of complete media (RPMI
1640 with 10% FBS, NEAA and antibiotic/antimycotic). This volume was layered over 4mL
of Ficoll-Paque™ PLUS in a 15mL conical centrifuge tube and centrifuged at 2,500rpm for
30min at 25°C. After centrifugation, the cells at the density interface were removed, and
washed with complete media. To assay for CD8+ cell activity, tumor infiltrating
lymphocytes were plated at a concentration of 2x106 cells/mL and stimulated with 5µM
Trp2 or Ova peptide for 6h at 37°C. The TIL were incubated with Fc Block, anti-CD8,
stained intracellularly for IFN-γ and analyzed by flow cytometry as described above.
Statistical Analysis
Statistical analysis was completed by using a two-tailed Student’s t-test. Data was qualified
as statistically significant if the P value was less than 0.05.
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Maximum solubility of Trp2 peptide in water was measured at 1.825mM after conversion to
a disodium salt, compared to 0.06mM of the trifluoracetate salt in water, an increase of 30.4
fold.
Our method of preparing (R)-DOTAP/Trp2 complexes by thin film hydration and extrusion
formed stable nano-sized complexes. We observed decreasing size with increasing
concentration of Trp2 incorporated, ranging from 120 to 87nm, for 0 to 1.5mM Trp2 used
for hydration, respectively (Figure 1A). All particles had a polydispersity index
measurement less than 0.1 (data not shown). Likewise, we observed a decrease in zeta
potential with increasing Trp2 dose incorporated, as the Trp2 peptide formulated as a
disodium salt, contains two exposed negative charges (on the aspartic acid and C terminus)
after conversion from a trifluoroacetate salt (pH 4) to a disodium salt (pH 9). Percent
entrapment was consistently high over a range of Trp2 doses (Figure 1B). Stability of the
complexes was measured over two weeks at 4°C, showing consistent size (no aggregation or
flocculation) (Figure 1C). TEM images of (R)-DOTAP/Trp2 (75nmol) show rod-like
particles with an average length and width of 78.8 ±29.8 and 32.9 ±6.8nm, respectively
(Figure 1D).
Tumor Growth Delay by Therapeutic Vaccination
Mice were inoculated with tumors on day 0, treated with (R)-DOTAP/Trp2 vaccines on day
6 with varying concentrations of Trp2 peptide, and tumor growth was followed for 20 days
(Figure 2). While (R)-DOTAP/Trp2 nanoparticles delivering 5nmol and 25nmol Trp2 had
no effect on tumor growth delay, delivery of 75nmol Trp2 adjuvanted by (R)-DOTAP was
able to show statistically significant tumor growth delay, with P<0.005 compared to control
mice. Shown in the Figure 2 inset, body weight of these tumor-bearing mice was also
monitored, and while no statistical difference exists, there was observable weight gain (due
to tumor size) in control, (R)-DOTAP/Trp2 (5nmol), and (R)-DOTAP/Trp2 (25nmol)
groups, that was not seen in the (R)-DOTAP/Trp2 (75nmol) group.
Multi-Organ IFN-γ Production by CD8+ T cells from Vaccinated Mice
Seven days after vaccination with various (R)-DOTAP/Trp2 nanoparticles, mice were
sacrificed and lymph organs of interest extracted and processed to single cell suspensions to
analyze Trp2 responsiveness in CD8+ populations. Cells from the spleen, tumor-draining
lymph node and vaccine draining lymph node (inguinal for both) were treated with Trp2 or a
non-specific peptide (Ova), as well as GolgiStop™ to prevent protein secretion for 6h and
then stained for CD8+ cells as well as intracellular IFN-γ accumulation (Figure 3). There
was no background from Ova-pulsed cells secreting IFN-γ for any group in any organ.
Naïve mice, tumor-bearing mice, 75nmol Trp2 peptide alone, and the lowest dose of (R)-
DOTAP/Trp2 (5nmol) showed no response to Trp2 pulse in any lymph organ.
Of the organs examined, splenocytes showed the highest population of responding cells,
with mice receiving the (R)-DOTAP/Trp2 (75nmol) vaccination producing the greatest
response at 0.3% of CD8+ cells (Figure 3A). (R)-DOTAP/Trp2 (25nmol) also showed some
response in CD8+ splenocytes, but at a much lower level (0.1%). Vaccine-draining lymph
node samples, showed an increased response in 75 and 25nmol Trp2 deliverable dose (0.1%)
(Figure 3B). Tumor-draining lymph nodes also showed the same response for 75 and
25nmol Trp2 deliverable dose (0.1%), which possibly indicates the contribution of the tumor
close to the skin’s surface, dampening the strong response of the 75nmol formulation to the
25nmol level at those locations (Figure 3B, C).
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In vivo Cytotoxic T Lymphocyte Assay
Seven days after vaccination, tumor-bearing mice were injected with Trp2- and Ova-pulsed
targets labeled with different levels of CFSE for 22h before sacrificing the mice and
removing the remaining cells (by processing the spleen). The purpose of this assay is to
evaluate if a vaccinated mouse can show specific lysis of targets presenting the antigen from
vaccination (Trp2 peptide). Unvaccinated tumor-bearing mice showed similar amounts of
specific lysis as 75nmol Trp2 peptide alone, and (R)-DOTAP/Trp2 (5nmol) and (25nmol)
doses (Figure 4). Seventy five nmol of peptide alone (without (R)-DOTAP), also showed
negligible amounts of specific lysis. However, (R)-DOTAP/Trp2 (75nmol), showed
significant specific lysis after 22h of in vivo incubation of Trp2- and Ova-pulsed targets.
This indicates that not only the dose of Trp2, but also the inclusion of (R)-DOTAP is crucial
to elicit a CTL response.
Tumor infiltrating lymphocytes
Seven days after vaccination, tumors were removed, minced and prepared as a single cell
suspension to detect the infiltrating CD3+CD4+ and CD3+CD8+ lymphocytes (Figure 5).
Twenty-five nmol and 75nmol Trp2 formulated in (R)-DOTAP were able to elicit
recruitment of both CD4+ and CD8+ T cells into the solid tumor (Figure 5). Nearly 1% of
the cells in the tumor mass of (R)-DOTAP/Trp2 (75nmol) vaccinated mice were CD3+CD8+
cells; 0.2% were identified as CD3+CD4+ cells. (R)-DOTAP/Trp2 (25nmol) had a less
profound effect, but quantifiable amounts of CD8+ and CD4+ T cells (0.3% and 0.1%,
respectively). Other groups (untreated tumor, 75nmol Trp2 peptide alone, and (R)-DOTAP/
Trp2 (5nmol)), showed lower than 0.1% CD4+ or CD8+ T cells out of the tumor mass.
When lymphocytes were isolated from tumors of vaccinated mice, reactivity to Trp2 was
examined. After a 6h pulse with Trp2 or Ova peptide (and GolgiStop™), cells were
examined for IFN-γ secretion (Figure 6). (R)-DOTAP/Trp2 (75nmol) showed statistically
significant response to Trp2 compared to all other groups, nearly 6% of all CD8+ TIL, with
P<0.005. There was some background IFN-γ secretion by Ova-pulsed cells in tumors of (R)-
DOTAP/Trp2 (75nmol) treated mice. Lower deliverable doses of Trp2 (25nmol and 5nmol),
and unvaccinated mice showed Trp2 reactivity by less than 1% of CD8+ TIL.
Discussion
Even with current advances in melanoma therapy (anti-CTLA4 mAb and small molecule
BRAF inhibitors), there still exists an opportunity to innovate and further refine therapeutic
treatment for aggressive melanoma decreasing side effects and honing specificity. Data
presented here has shown that peptide-based vaccines offer a safe and significant
advancement against an aggressive murine melanoma solid tumor model.
Overcoming formulation difficulty of the Trp2 peptide
Others have made efforts to combat the difficulty in formulating Trp2 peptide in an aqueous
solution, ranging from looking at modifying the epitope to conjugation to larger proteins to
enhance delivery.
Tang et. al. investigated increasing Trp2 binding efficacy to HLA-A201 by modifying the
anchor residues.10 Modifying SVYDFFVWL to SMYDFFVWL (or a Trp2 2M
modification) was delivered in comparable doses to what we’ve shown in this study. When
100µg (63.8nmol) was delivered with 50µg of the PADRE T helper epitope
(AKFVAAWTLKAAA) in incomplete Freund’s adjuvant (IFA) to a transgenic HLA-A2.1/
Kb model, higher amounts of IFN-γ was elicited compared to vaccination with wild type
peptide. Trp2 has also been modified into (SIYDFFVWL), called “deltaV” which showed
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increased T cell responsiveness to Trp2 by intracellular IFN-γ staining. However, when
deltaV was delivered with poly(I:C) and anti-CD40 and later boosted with these two
adjuvants, no increased growth delay was seen with in a prophylactic B16F10 model
compared to wild type peptide.11 Other inventive ways to deliver Trp2 to APCs have been
published. Kou et. al. developed a ScFv-peptide conjugate to target Trp2 to CD11c+
dendritic cells in vitro.12 This conjugate has shown stimulation of T cell proliferation, but
Trp2 peptide alone showed comparable levels in the study. As a self-antigen, suppression
mechanisms also exist to prevent the expansion of T cells in a tumor environment, thus the
difficulty of low doses of Trp2 in (R)-DOTAP/Trp2 (5nmol) and (25nmol) in eliciting a
IFN-γ response (Figure 3A).
Common models for murine melanoma rarely include therapeutic treatments in advanced
solid tumors
An advanced solid tumor model is rarely investigated in Trp2 peptide-based vaccines; more
often, a prophylactic model or CTL characterization is tested.10–13 However, it is unlikely
that a prophylactic melanoma vaccine would ever be commercially developed. The potential
side effect of vitiligo is not likely to be traded for the possibility of protection, particularly as
Trp2 peptide reactivity has been tied to this autoimmune depigmentation.22
Trp2 peptide encapsulated in liposomes with p53 peptide, PADRE T helper peptide, CpG
oligos together to was able to prevent tumor establishment when delivered six days after
inoculation of 1x104 B16F10 cells.14 However, as a measure of tumor challenge, only two-
thirds of the control group ever established tumors. Another liposomal treatment required
CpG to show a therapeutic response, with two doses of liposomal Trp2 and a separate
formulation of liposomal CpG delivered in a 1x105 B16F10 subcutaneous model.15
However it is not clear from the data published from either study, that tumors were palpable
or even visible when treated. Our choice of an advanced tumor model, 3x105 B16F10-luc
cells for subcutaneous inoculation, was based on all mice having measurable tumors on day
6, compared to inoculation with fewer cells (data not shown). Also, while CpG is a well
characterized TLR9 agonist, the elegance of liposomal (non-viral) delivery is not aptly
executed by the above two studies, with multiple adjuvants and multiple delivery devices
needed. Our adjuvant, (R)-DOTAP also acts as the carrier for Trp2 peptide, simplifying the
vaccine to active ingredients only, one stable and versatile particle that can show response
against an established tumor (Figure 1, Figure 2).
Viral delivery of Trp2 peptide or protein has shown non-robust immunity compared to the
statistically significant tumor growth delay we see with (R)-DOTAP/Trp2 nanoparticles
delivering 75nmol of antigen (Figure 2) in an aggressive solid tumor model. Recombinant
adeno-associated virus (rAAV) carrying Trp2 cDNA delivered 22 days before tumor
challenge was unable to induce tumor growth delay.16 Delivered at a dose of 1010 or 1011
rAAV viral particles were unable to protect against a tumor challenge of 3x105 B16F10,
even with the addition of other adjuvants, including CpG oligonucleotides and imiquimod.
Interestingly, like (R)-DOTAP/Trp2 (25nmol), the rAAV-Trp2+CpG treatment showed an
IFN-γ response from splenocytes, however, was not able to break tolerance and show any
tumor growth delay. Multiple doses of Trp2 peptide conjugated to exposed lysines on the
tobacco mosaic virus (TMV) was delivered with CpG oligonucleotides prior to inoculation
with 5x104 B16F1, showing no statistical difference compared to control or TMV with a
different melanoma antigen p15e.13 Additionally, in this challenge model, tumor penetration
was 11 out of 12.
Dendritic cells pulsed with Trp2 peptide have also shown ineffective responses in both
prophylactic and simultaneous tumor models.7 However, when the HIV TAT protein
transduction domain was ligated to a 472 amino acid sequence from the Trp2 protein or to
Vasievich et al. Page 8













the Trp2 peptide (180–188 amino acids); both showed better tumor prevention compared to
dendritic cells pulsed with Trp2 peptide only.23, 24 This supports the need for an intracellular
delivery mechanism like (R)-DOTAP/Trp2 formulations to ensure Trp2 peptide is presented
on MHC class I. An interesting result of the above mentioned study showed in vitro CTL
reactivity to B16 cells correlated with tumor size. Our in vivo CTL results on day 13, when
all groups had statistically indistinguishable tumors, is an early indicator of the ability of a
formulation to cause statistically significant tumor growth delay (Figure 4, Figure 2).
Our choice to use an aggressive subcutaneous model versus a lung metastatic model was to
utilize the existence of a suppressive tumor microenvironment. Many types of suppressive
immune cell exist in the tumor that tolerize the immune system to the tumor’s presence, and
combating these cell types with possible therapies should be the next frontier of
immunotherapy.25 With a larger tumor mass existing in the solid tumor model versus the
metastatic model, the bar is higher for a vaccine to break this tolerance. In a model of
transgenic Trp2 peptide specific T cells, the adoptive therapy of T cell transfer was able to
cause statistically significant decrease in lung nodules (P>0.0001), however, had no effect
whatsoever on any tumor growth delay in a solid tumor model.26 The adoptive cell transfer
was able to show nearly 98% specific lysis of Trp2 pulsed targets in an in vivo CTL assay,
however, not able to reject the 2x105 B16F10 solid tumor inoculation. Even with the
addition of a Trp2-pulsed dendritic cell vaccine, no significant tumor growth delay was
observed in the solid tumor model. While Trp2 specific T cells were detected in the solid
tumor, they did not affect tumor growth, unlike our detection of infiltrating T cells that
correlated with tumor growth delay (Figure 5, Figure 6).
Future directions in melanoma immunotherapies should tackle established tumors with an
existing suppressive microenvironment. As shown by the ipilimumab approval and
increasing numbers of biologic drugs; targeting suppressive mechanisms in and around the
tumor, shutting down this protective barrier could empower immunotherapy to become the
standard of care over conventional chemotherapy. Anti-CTLA4 antibodies are already being
tested in a wide range of tumors, expanding the application beyond melanoma.27 The ability
and strength of (R)-DOTAP to break tolerance in this model after one immunization and the
flexibility of the adjuvant to deliver an adequate dose of antigen in a stable formulation
pushes it forward to be tested in other aggressive tumor models and possibly into clinical
development.
Abbreviations
APCs antigen presenting cells
CFSE carboxyfluorescein succinimidyl ester
CTL cytotoxic T lymphocyte
IFA incomplete Freund’s adjuvant
irAE immune-related adverse events
MHC major histocompatibility complex
rAAV recombinant adeno-associated virus
(R)-DOTAP (R)-1,2-dioleoyl-3-trimethylammonium-propane
TIL tumor infiltrating lymphocytes
TMV tobacco mosaic virus
Trp2 tyrosinase-related protein 2
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Figure 1. R-DOTAP/Trp2 characterization and stability
(A) Size, charge and (B) entrapment of Trp2 was evaluated on (R)-DOTAP/Trp2 complexes
with varying concentrations of Trp2, n=3. (R)-DOTAP/Trp2 nanoparticles were stored at
4°C and (C) size measured over a period of two weeks, n=3. Experiment was repeated twice.
In (C), the size measured from 0nmol Trp2 was the same as that with 5nmol Trp2,
overlaying completely at every time point. (D) TEM image of (R)-DOTAP/Trp2 (75nmol)
complexes. A total of 210 particles from 3 different fields were measured. Particle
dimensions were calculated by measuring the longest dimension and the perpendicular
diameter.
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Figure 2. B16F10-luc tumor growth inhibition by (R)-DOTAP/Trp2 complexes in vivo
Six week old female C57BL/6 mice were inoculated with 3x105 B16F10-luc cells s.c. in the
abdomen on day 0. On day 6, treatments were s.c. injected into the opposite side of the
abdomen. Lipid formulations delivered contained 300nmol (R)-DOTAP and varying doses
of Trp2 peptide. Tumors were measured with calipers with area calculated as length times
width. The inset represents body weight tracked over time. Seven mice were used per group.
Experiment was repeated twice. *: P<0.005.
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Figure 3. Multi-organ IFN-γ production from (R)-DOTAP/Trp2 vaccinated mice
(A) Splenocytes, (B) vaccine draining lymph nodes, or (C) tumor draining lymph nodes
were isolated (on day 13) from tumor-bearing mice treated with (R)-DOTAP/Trp2 (300nmol
(R)-DOTAP/ varying Trp2 doses) (on day 6). Resulting cells were pulsed with Trp2 or an
irrelevant peptide (Ova) for 6h, washed, and stained for CD8 and IFN-γ. The numbers on the
contour plots indicate percentage of IFN-γ+CD8+ T cells out of all CD8+ T cells. Data from
one representative mouse is shown, with five to seven total animals per group. Experiment
was repeated twice.
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Figure 4. In vivo CTL shows specific lysis of Trp2-pulsed targets elicited by (R)-DOTAP/Trp2
(75nmol) vaccination
Targets pulsed with Trp2 or an irrelevant peptide (Ova) were stained with high (Trp2) or
low (Ova) concentrations of CFSE, injected into (R)-DOTAP/Trp2 vaccinated mice and in
vivo killing was allowed for 22h, then spleens removed and analyzed by flow cytometry.
Percent specific lysis, P<0.05 between (R)-DOTAP/Trp2 (75nmol) and other groups. Three
to five mice were used per group. Experiment was repeated twice.
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Figure 5. CD3+ Tumor Infiltrating lymphocytes are higher numbers with higher vaccination
doses
CD4+ and CD8+ tumor infiltrating T cells assayed from tumors of mice treated with varying
doses of (R)-DOTAP/Trp2. Cells were gated on CD3+, and percentages represent
CD3+CD4+ or CD3+CD8+ out of total numbers of cells in the tumors. Data from one
representative animal is shown, three to four mice were used per group. Experiment was
repeated twice.
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Figure 6. Tumor infiltrating lymphocytes respond to Trp2 after a high vaccination dose
TIL were isolated from tumors of mice vaccinated with varying doses of (R)-DOTAP/Trp2,
pulsed for 6h with Trp2 or an irrelevant peptide (Ova) and analyzed for intracellular IFN-γ
in CD8+ cells. Percentages are IFN-γ+CD8+ cells out of all CD8+ cells., *: P<0.005. Three
mice were used per group. Experiment was repeated twice.
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